glp-1 receptor agonists effects on cardiovascular risk reduction Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction Effects of GLP-1 receptor agonists

2015), mice (Noyan-Ashraf et al

Perhaps GLP-1 receptor agonists fit the bill as the long awaited holy grail for interventional weight loss

In conclusion, both SGLT2-i and GLP1-RA seem to have several effects on RAAS, though additional studies are needed to clarify this relationship

Important points for patients to understand: No proven link exists between GLP-1 medications and pancreatic cancer based on extensive research involving hundreds of thousands of patients Type 2 diabetes itself carries an increased risk of pancreatic cancer, independent of treatment The absolute risk of pancreatic cancer remains low, even in higher-risk populations Regular medical follow-up allows for monitoring of overall health and early detection of any concerns When to contact your GP or seek medical attention: Patients should be aware of symptoms that warrant prompt medical evaluation, including: Persistent severe abdominal pain , particularly if it radiates to the back (potential sign of pancreatitis) if this occurs, stop taking your GLP-1 medication and seek urgent medical advice via your GP, NHS 111, or 999 if severe Unexplained weight loss (not attributable to the expected effects of GLP-1 therapy) New-onset jaundice (yellowing of skin or eyes) this requires immediate medical attention Persistent nausea and vomiting Unexpected deterioration in diabetes control or new-onset diabetes without typical risk factors Making informed treatment decisions: Patients considering or currently taking GLP-1 receptor agonists should: Discuss any concerns about cancer risk openly with their healthcare provider Understand their individual risk factors for pancreatic disease Maintain regular follow-up appointments as recommended Report any new or concerning symptoms promptly Continue treatment as prescribed unless advised otherwise by a healthcare professional Report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) Lifestyle factors that reduce pancreatic cancer risksuch as smoking cessation, maintaining a healthy weight, and moderating alcohol consumptionremain important regardless of medication use

While these agents are not recommended during pregnancy, their use in the preconception, periconception, and postpartum periods is increasing

In a phase II trial, participants with obesity were randomly assigned to various doses of retatrutide from 14 , 8, or 12 mg or a placebo for 48 weeks [19]